checkpoint inhibitors

Checkpoint inhibitors are immunotherapy drugs that release the natural "brakes" on the immune system so it can recognize and attack cancer cells. Cancer cells often display proteins (like PD-L1) that tell immune cells to stand down; checkpoint inhibitors block those signals. For pleural mesothelioma, the combination of nivolumab (a PD-1 inhibitor) and ipilimumab (a CTLA-4 inhibitor) is now an approved first-line option.

Origin

The concept grew out of decades of immunology research into "immune checkpoints", molecular brakes that prevent the immune system from attacking healthy tissue. James Allison and Tasuku Honjo shared the 2018 Nobel Prize in Medicine for identifying CTLA-4 and PD-1, respectively, as targets that could be blocked to unleash anti-tumor immunity. The FDA approved the nivolumab/ipilimumab combination for unresectable pleural mesothelioma in October 2020 based on the CheckMate 743 trial.

Significance in Asbestos Context

Checkpoint inhibitors have changed the standard of care for pleural mesothelioma, which historically had very limited treatment options. The CheckMate 743 trial showed that nivolumab plus ipilimumab improved overall survival compared with chemotherapy, particularly in patients with non-epithelioid (sarcomatoid or biphasic) mesothelioma, who tend to respond poorly to chemotherapy. Patients should ask their oncologist whether immunotherapy (alone, combined, or alongside chemotherapy) is appropriate for their histologic subtype and stage, and whether testing for PD-L1 expression or enrollment in a clinical trial makes sense. Because these treatments are recent, expensive, and ongoing, documentation of immunotherapy in medical records is also relevant to the medical-cost and pain-and-suffering portions of an asbestos claim.

Example Sentence

After her biphasic mesothelioma diagnosis, the oncologist recommended starting nivolumab and ipilimumab, checkpoint inhibitors that had shown a survival benefit in patients with her subtype.

Related Terms

Immunotherapy, Mesothelioma, PD-1, CTLA-4, CheckMate 743, Pemetrexed

Notes

• Ask your oncologist specifically about nivolumab plus ipilimumab if you have pleural mesothelioma, and whether your histologic subtype (epithelioid, sarcomatoid, or biphasic) affects the recommendation.
• Watch for and promptly report immune-related side effects — rash, colitis (diarrhea), thyroid changes, pneumonitis (cough/shortness of breath), or fatigue — because early treatment with steroids can prevent serious complications.
• Keep copies of all infusion records, scan reports, and treatment summaries; these document both your medical course and the costs that may be recoverable in an asbestos claim.
• Ask whether a clinical trial is available. New checkpoint combinations and biomarkers (PD-L1, tumor mutational burden) are active areas of mesothelioma research.